Walleye Capital LLC Makes New Investment in Ralliant Corporation $RAL

Walleye Capital LLC purchased a new stake in Ralliant Corporation (NYSE:RAL) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 108,790 shares of the company’s stock, valued at approximately $4,525,000.

Several other institutional investors and hedge funds also recently made changes to their positions in RAL. Dodge & Cox raised its position in shares of Ralliant by 13.3% during the fourth quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock worth $621,849,000 after acquiring an additional 1,434,376 shares during the last quarter. Viking Global Investors LP acquired a new stake in Ralliant during the 2nd quarter valued at approximately $257,200,000. Millennium Management LLC increased its position in Ralliant by 172.4% during the 4th quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock valued at $253,175,000 after purchasing an additional 3,147,660 shares during the period. State Street Corp acquired a new position in shares of Ralliant in the 2nd quarter worth approximately $213,096,000. Finally, Invesco Ltd. lifted its position in shares of Ralliant by 4.9% in the 4th quarter. Invesco Ltd. now owns 4,059,588 shares of the company’s stock worth $206,674,000 after purchasing an additional 187,898 shares during the period.

Analyst Ratings Changes

Several research firms have recently weighed in on RAL. Oppenheimer increased their price objective on shares of Ralliant from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 13th. Morgan Stanley upped their price target on shares of Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a research report on Tuesday, June 23rd. Truist Financial reiterated a “buy” rating and set a $68.00 price target (up from $53.00) on shares of Ralliant in a report on Wednesday, May 13th. Barclays lifted their price objective on Ralliant from $52.00 to $67.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 13th. Finally, TD Cowen boosted their price objective on Ralliant from $55.00 to $70.00 and gave the company a “buy” rating in a research note on Wednesday, May 20th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Ralliant has an average rating of “Moderate Buy” and a consensus price target of $73.00.

Ralliant Stock Performance

NYSE:RAL opened at $70.12 on Thursday. The company has a fifty day moving average of $66.03 and a 200-day moving average of $53.55. The firm has a market capitalization of $7.85 billion and a P/E ratio of -6.41. The company has a quick ratio of 1.05, a current ratio of 1.61 and a debt-to-equity ratio of 0.73. Ralliant Corporation has a twelve month low of $37.27 and a twelve month high of $75.41.

Ralliant (NYSE:RAL) last issued its earnings results on Tuesday, May 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.08. The business had revenue of $534.60 million for the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. Ralliant’s revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. As a group, sell-side analysts anticipate that Ralliant Corporation will post 2.64 EPS for the current year.

Ralliant Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th were given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend was Monday, June 8th. Ralliant’s dividend payout ratio is -1.83%.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.